Marcus Schabacker - 23 Dec 2025 Form 4 Insider Report for Enveric Biosciences, Inc. (ENVB)

Role: Director
Signature: /s/ Marcus Schabacker
Issuer symbol: ENVB
Transactions as of: 23 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 30 Dec 2025, 16:39:53 UTC
Previous filing: 11 Oct 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schabacker Marcus	Director	245 FIRST STREET, RIVERVIEW II, 18TH FLOOR, CAMBRIDGE	/s/ Marcus Schabacker	30 Dec 2025	0001645282

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENVB	Common Stock	Award	$0	+7,633	+2859%	$0.000000	7,900	23 Dec 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
F2	On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.

Content

Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.

On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits.